General information about U.S. regulatory definitions, not legal or medical advice.

If you searched for "Cornerstone Bio Labs," start with a disambiguation: Cornerstone Bio Labs (cornerstonebiolabs.com) and Cornerstone Peptide (cornerstonepeptide.com) are different websites operating under different names, and Cornerstone Peptide is not affiliated with, endorsed by, or a reseller for Cornerstone Bio Labs. What follows is a primary-sourced explainer of how U.S. law classifies the research-use peptides sold under labels like these — including what moved in 2026.

Is Cornerstone Bio Labs the same company as Cornerstone Peptide?

They are different names on different sites, and the affiliation question we can answer first-hand is our own: Cornerstone Peptide is not affiliated with, endorsed by, or a reseller for Cornerstone Bio Labs. Beyond that, this piece makes no claim about any other company's ownership or corporate structure — and it would not change the answer that matters, because federal law does not classify these products by who sells them. Under 21 U.S.C. § 321(g)(1), clause (C) makes an article a "drug" when it is "intended to affect the structure or any function of the body," and clause (B) separately reaches the disease-directed uses it enumerates. Intended use — not the seller, not the label — is the test. Vendor marketing claims, purity percentages, third-party testing, and certificates of analysis are not confirmable on any government or peer-reviewed source, for either name or any other vendor.

Is BPC-157 FDA-approved?

No. FDA's own Drugs@FDA database holds no approved application with BPC-157 as an active ingredient: the openFDA query returns openFDA's `NOT_FOUND` response — "No matches found!" — instead of a drug record, while the identical endpoint returns a full application record for an approved product such as NDA 215256. A 2025 peer-reviewed review in *Pharmaceuticals* agrees, stating BPC-157 "has not been approved for use in standard medicine by the FDA" and other global regulators, "has not been prescribed as a drug, though it is widely accessible on the black market," and that "most, if not all, studies are limited to small animal models (i.e., rats and mice)," per PMC11859134.

The clinical record is thin by the numbers. BPC-157 is a pentadecapeptide — 15 residues, molecular weight 1419.55 Da, isolated from human gastric juice (PMC11859134). The U.S. trials registry holds a two-study set with BPC-157 as an intervention — NCT07437547, a Phase 2 hamstring-strain study, and NCT02637284, a Phase 1 safety and pharmacokinetics study — and no completed Phase 2 or Phase 3 efficacy trial. Recruitment status is a live field that a sponsor can change without notice, so rather than date-stamp a snapshot here, run the query yourself: the ClinicalTrials.gov v2 API returns each record's current `overallStatus` and last-update date. That thinness matters legally too: 21 U.S.C. § 355(a) bars any new drug from interstate commerce "unless an approval of an application filed pursuant to subsection (b) or (j) is effective."

Why do research-peptide sites say "for research use only"?

Because the statute defines a drug by intended use, and the disclaimer is an attempt to disclaim that use. But the phrase itself is not what makes research use lawful. "For Research Use Only" is a labeling statement FDA defines by regulation for in vitro test products (IVDs) — 21 C.F.R. § 809.10(c)(2)(i) directs that an in vitro product in the laboratory research phase bear that statement — and that rule governs test products, not injectable peptides.

The drug provisions do contain an investigational-use exemption, and that is the stronger point: 21 U.S.C. § 355(i) authorizes exemptions for drugs "intended solely for investigational use by experts qualified by scientific training and experience to investigate the safety and effectiveness of drugs," implemented through the IND regulations at 21 C.F.R. Part 312. So a research exemption exists — it is just granted through a filed, FDA-reviewed application with a sponsor, a protocol, and investigator qualifications, rather than by printing six words on a vial sold to anyone who checks a box at checkout.

The consequences stack. A drug is misbranded unless its labeling bears "adequate directions for use" and adequate warnings (21 U.S.C. § 352(f)), and introducing a misbranded drug — or an article in violation of § 355 — is a prohibited act under 21 U.S.C. § 331(a) and (d), carrying imprisonment of "not more than one year" or a fine of "not more than $1,000," rising to three years or $10,000 with a prior conviction or "the intent to defraud or mislead" (21 U.S.C. § 333(a)). Read those 1938-era dollar figures as historical text, not as the exposure: the general federal fine schedule at 18 U.S.C. § 3571 supplies the applicable maximum unless the offense statute specifically exempts itself from it. Nor is "sell it as a supplement" an escape hatch: an article approved as a new drug, or authorized for investigation as a new drug with substantial clinical investigations instituted and made public, is excluded from the definition of "dietary supplement" — provided it was not marketed as a dietary supplement or as a food before that approval or authorization — under 21 U.S.C. § 321(ff)(3)(B).

Is U.S. law on research peptides changing in 2026?

It is in motion, but as of July 24, 2026 nothing has changed a research vial's status. FDA's Pharmacy Compounding Advisory Committee is meeting July 23–24, 2026 at the White Oak Campus in Silver Spring, MD, to consider seven peptide families for the 503A Bulks List: on July 23, BPC-157 (free base and acetate), KPV, TB-500, and MOTs-C; on July 24, emideltide, semax, and epitalon. The public docket is FDA-2025-N-6895, with the final comment deadline July 22, 2026, per the Federal Register notice. This page was written while that meeting was underway — for what the committee actually recommended, read the docket, not this paragraph.

Read the mechanics before reading anything into that meeting. Compounded drugs are exempt from only three requirements — cGMP, the adequate-directions labeling rule, and new-drug approval — and only when compounded by a licensed pharmacist or physician for an identified patient, from a bulk substance that meets a USP/NF monograph, is a component of an approved drug, or appears on FDA's list (21 U.S.C. § 353a). None of that reaches a vial shipped to a consumer, and none of those conditions is written to be satisfied by an advisory committee's advice. Separately, on May 1, 2026 FDA proposed not to include semaglutide, tirzepatide, or liraglutide on the 503B Bulks List, stating that "clinical need" does not encompass supply shortages, convenience, or cost (FR doc. 2026-08552).

How does a research peptide differ from Wegovy or Zepbound?

The difference is premarket review, documented down to the application number. Wegovy (semaglutide) is NDA 215256, sponsor Novo Nordisk, approved June 4, 2021, marketing status prescription — the application record is in Drugs@FDA, and its DailyMed label is a human prescription drug label for subcutaneous injection with FDA-reviewed indications in adults with cardiovascular disease plus obesity or overweight, and in adults and patients 12 and older with obesity. Zepbound (tirzepatide) is NDA 217806, sponsor Eli Lilly, approved November 8, 2023, likewise on file in Drugs@FDA, with a DailyMed label covering adults with obesity or overweight plus a comorbidity, and moderate-to-severe obstructive sleep apnea.

Approval attaches to those specific products, not to any vial of the same molecule sold as a research chemical. A drug that "is not safe for use except under the supervision of a practitioner" is prescription-only, and dispensing outside that channel is deemed misbranding (21 U.S.C. § 353(b)(1)).

What do FDA's adverse-event records show for BPC-157?

Very little data, and it should be read narrowly. FDA's adverse event reporting system contains 15 reports naming BPC-157 as of the openFDA data refresh dated April 28, 2026. The most frequent reaction term is drug ineffective, at 3 reports; below it sits a cluster of terms at 2 reports each, including abdominal discomfort, balance disorder, drug intolerance, dyspnoea, erythema, flushing, headache, hypersensitivity, and nausea. The openFDA drug/event endpoint returns the complete ranked list, not just this excerpt. One report in the set, received June 14, 2021, lists "product sterility lacking" alongside injection-site swelling and erythema.

Two caveats are essential: openFDA states the results are unvalidated and not for medical decision-making, and spontaneous reports do not establish causation — 15 is a count of filings, not a harm rate, and the 2025 review's own summary of the underlying science is that it rests on small animal models (PMC11859134).

If you are comparing research-peptide vendors, apply that same evidence standard to whatever you read next — including this site. Browsing the Cornerstone Peptide catalog settles none of the regulatory questions above: nothing listed there is an approved drug, and no vial from any vendor is. What the catalog does give you is each item's stated identity and analytical documentation, so you can hold a specific product to the same standard of proof this article has held every claim to.

Frequently asked questions

Is Cornerstone Bio Labs the same company as Cornerstone Peptide? No — different websites operating under different names, and Cornerstone Peptide is not affiliated with, endorsed by, or a reseller for Cornerstone Bio Labs. Either way, legal status is fixed by intended use for every vendor alike (21 U.S.C. § 321(g)(1)).

Is BPC-157 FDA-approved? No. Drugs@FDA returns no approved application with BPC-157 as an active ingredient, and no new drug may be sold across state lines without one (21 U.S.C. § 355(a)).

Why do peptide sites label products "for research use only"? Because a drug is defined by intended use, and the phrase tries to disclaim it. "For Research Use Only" is a labeling statement FDA defines for in vitro test products (IVDs) at 21 C.F.R. § 809.10(c)(2)(i); the drug provisions' actual research exemption runs through an FDA-reviewed IND under 21 U.S.C. § 355(i) and 21 C.F.R. Part 312, not through label wording.

Did FDA change the rules on peptides in 2026? Not as of July 24, 2026. The committee is meeting to *consider* seven peptide families for the 503A Bulks List, per the Federal Register notice, and § 503A reaches only a pharmacist or physician compounding for an identified patient (21 U.S.C. § 353a).

How is a research peptide different from Wegovy or Zepbound? Wegovy is NDA 215256 (approved June 4, 2021) and Zepbound is NDA 217806 (approved November 8, 2023) — prescription-only products with FDA-reviewed labels. Approval attaches to those products, not to the molecule, and dispensing a prescription drug outside that channel is misbranding (21 U.S.C. § 353(b)(1)).

How many adverse-event reports name BPC-157? Fifteen, as of the openFDA data refresh dated April 28, 2026, per the openFDA drug/event endpoint. These are unvalidated spontaneous reports and do not establish that BPC-157 caused any reaction.